In Opposition to Maine LD 1636 (Senator Claxton)

February 15, 2022

Position: PhRMA respectfully opposes LD 1636 because it allows the government to set the price of prescription drugs, which could limit the prescription options available to patients in Maine, discriminate against patients, stifle innovation, and raise significant legal concerns.

This proposed legislation requires state-regulated commercial insurance plans and pharmacies to cap the amount paid for prescription medicines at a Canadian reference price. This legislation could harm patient health outcomes because if a medicine cannot be purchased at the reference price, it will not be available to patients—inserting the government between health care provider and patient decision making. This legislation also could jeopardize the competitive market that works to drive down drug prices if the number of medicines available on the market is reduced.

Implementing price controls at a time when the industry has been tirelessly dedicated to finding treatments and vaccines for COVID-19 diverts industry resources elsewhere and risks current and future innovation. We are in a new era of medicine that is bringing revolutionary, innovative treatments, therapies, and cures to patients. Last year alone, the cancer death rate saw the biggest one-year drop in history.1 Unfortunately, this radical policy could freeze new, life-saving innovation and force patients to face the uncertainty of a health care system where the government sets prices for critical medicines, similar to what is done in other countries.

This legislation ignores that there are meaningful policies for addressing affordability without importing government price setting that could reduce treatment options.

PhRMA is increasingly concerned that the substantial rebates and discounts paid by pharmaceutical manufacturers, approximately $187 billion in 2020,2 do not make their way to offsetting patient costs at the pharmacy counter. Patients need concrete reforms that will help lower the price they pay for medicines at the pharmacy, such as making monthly costs more predictable, making cost-sharing assistance count toward a plan’s out-of-pocket spending requirements, and sharing negotiated savings on medicines with patients. These policies can be done without importing international price setting, which can reduce the options available to treat patients.

---

**Price controls can limit access to needed medicines.**

Allowing the government to set prices at the lowest price in Canada could restrict patients’ access to medicines by reducing the availability of life-saving therapies in the state. For example, if a payor cannot obtain a therapy at the state-prescribed price, and/or if a pharmacy or dispensing provider cannot stock the drug because it too cannot meet the state-prescribed price, then the medicine will not be available to patients. Further, allowing the government to set a price could prevent a health care provider from choosing the best treatment for a patient, thus impacting patient health outcomes.

**By importing prices set in other countries, this legislation also imports cost-effectiveness analyses that are known to be discriminatory.**

Studies using cost-effectiveness analysis (CEA) rely on the use of discriminatory Quality Adjusted Life Years (QALYs) and cost-per-QALY thresholds. Developed from population averages, QALYs ignore important variability in patients’ individual needs and preferences. Experts have identified that QALYs discriminate against people with disabilities by placing a lower value on their lives. A report issued by the National Council on Disability in 2019 “found sufficient evidence of the discriminatory effects of QALYs to warrant concern, including concerns raised by bioethicists, patient rights groups, and disability rights advocates about the limited access to lifesaving medications for chronic illnesses in countries where QALYs are frequently used.”

In countries that rely on CEA to determine coverage and payment, like Canada, many patients face significant restrictions on access to treatments, including those diagnosed with cancer, diabetes, and rare diseases. An analysis noted that these types of cost-effectiveness assessments and recommendations based on population-averages fail to properly adjust to the demands of an evolving health care system and do not reflect the rapid pace of the science, or the needs and preferences of the patients.

**International reference pricing could threaten drug development and replaces market competition with government price setting.**

This legislation replaces market competition with government price setting or price controls, basing U.S. medicine prices on the policies of other governments that ration care in their own countries. The legislation threatens to drastically reduce development of new medicines at a time of remarkable scientific promise, undermining U.S. global leadership in biopharmaceutical innovation. Government price setting diminishes the incentive for biopharmaceutical manufacturers to invest in the research and development of new medicines. By requiring state-regulated commercial insurance plans and pharmacies to cap the amount paid for prescription medicines at a reference price, this creates a price control on these medicines that could have the long-term effect of decreasing access to medications.

On average, it takes more than 10 years and $2.6 billion to research and develop a new medicine. Just 12% of drug candidates that enter clinical testing are approved for use by patients. Efforts to

---

4 Context Matters. NICE Limits Reimbursement for Oncology Products beyond EMA Product Labeling. May 2014.
Impart price controls on innovative manufacturers could chill the research and development of new medicines by taking away the incentives that allow manufacturers to invent new medicines.

For years, Canada has imposed price controls and other measures that significantly undervalue innovative medicines developed in the United States. Research shows that U.S. patients enjoy earlier and less restrictive access to new therapies.\(^5\) This is reinforced by the United States Department of Health and Human Services’ own analysis of Medicare Part B drugs which showed that only 11 of the 27 drugs examined (41%) were available in all 16 comparator countries, nearly all of which have single payer health care systems.\(^6\)

In fact, American patients have faster access to more medicines than patients anywhere else in the world, and doctors and patients work together to decide which medicine is right for them. In countries that use international reference pricing and other government price controls, patients can access fewer new medicines and face long treatment delays. Nearly 90% of new medicines launched since 2011 are available in the U.S. compared to just 50% in France, 46% in Canada, and 41% in Ireland – countries that use some form of international reference pricing.\(^7\) Even the medicines available in these countries take much longer to reach patients. On average, patients must wait at least 18 months longer in France, 15 months longer in Canada, and 20 months longer in Ireland than in the U.S.

**This legislation raises significant legal concerns.**

The proposed legislation raises constitutional concerns under the Supremacy Clause because it would restrict the goal of federal patent law, which is to provide pharmaceutical patent holders with the economic value of exclusivity during the life of a patent. Congress determined that this economic reward provides appropriate incentive for invention, and Maine is not free to diminish the value of that economic reward. Specifically, in the case of *BIO v. District of Columbia, 496 F.3d 1362 (2007)*, the U.S. Court of Appeals for the Federal Circuit overturned a District of Columbia law imposing price controls on branded drugs, reasoning that the law at issue conflicted with the underlying objectives of the federal patent framework by undercutting a company’s ability to set prices for its patented products. The court’s decision stated that “[t]he underlying determination about the proper balance between innovators’ profits and consumer access to medication …is exclusively one for Congress.”

This legislation gives the Superintendent of Insurance broad discretion to determine which products will be subject to a price control, and biopharmaceutical manufacturers are not provided due process at any stage of the Superintendent’s determinations. In addition, there is no clear mechanism for a biopharmaceutical company to appeal a penalty from the Superintendent of Insurance and/or Attorney General.

---


Finally, this legislation regulates extraterritorial transactions and discriminates against manufacturers that sell patented products in other nations, raising Dormant Commerce Clause and Foreign Commerce Clause concerns respectively.

PhRMA recognizes the access challenges faced by patients in Maine with serious diseases. However, this legislation could limit the treatments available to patients and stifle innovation. PhRMA stands ready to work with the legislature to develop market-based solutions that help patients better afford their medicines at the pharmacy counter.

For these reasons, we urge legislators to vote no on LD 1636.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested more than $1 Trillion in the search for new treatments and cures, including an estimated $91.1 billion in 2020 alone.